A Study in Schizophrenic Patients

NCT01125358 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

82

Enrollment

INDUSTRY

Sponsor class

Stopped The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population.

Conditions

Schizophrenia

Interventions

DRUG: LY2140023
DRUG: Placebo

Sponsor

Denovo Biopharma LLC